The Australian Adrenoleukodystrophy (ALD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP). Adrenoleukodystrophy is a result of fatty acid build-up caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions. Adrenoleukodystrophy is a fatal progressive neurogenerative disorder affecting brain white matter. Adrenoleukodystrophy is most commonly observed in childhood and present in both males and females; mainly affects men.
Because of the increased demand for products, the major industry players are investing in research and development to develop new items. This, in turn, is expected to fuel market expansion. Government measures to improve healthcare infrastructure result in increased patient access, which presents a substantial business potential.
Surge in the number of patients is driving the market growth of Adrenoleukodystrophy. Rising awareness about Adrenoleukodystrophy leads to increase in potential in research treatment. Moreover, rise in support and funds for research into new ALD treatments contribute to drive the market growth during the forecast period.
The key industry players are engaged in the development of new products by investment in research & development owing to a rise in the demand for products. This, in turn, is estimated to drive the market growth. Government initiatives to improve healthcare infrastructure leads to an increase the patient access and thereby offers significant.
Major Types of Adrenoleukodystrophy
Based on diagnosis, the Adrenoleukodystrophy Therapeutics market is bifurcated into blood test, molecular genetic testing, newborn screening, ACTH stimulation test, magnetic resonance imaging (MRI), and others. The blood test used to measure the levels of very long-chain fatty acids in the blood plasma and if these levels are notably high then, physicians will order genetic testing to confirm diagnosis. Newborn screening is a special type of screening test that newborns receive to see if they have certain diseases. An increase in the concentration of ACTH leads to rise in cortisol in the blood plasma indicated by ACTH stimulation test. MRI allows physicians to see whether the brain has been damaged, including the loss of myelin in the cerebral white matter.
On the basis of therapeutics, the Adrenoleukodystrophy Therapeutics market is segmented into allogeneic hematopoietic stem cell transplantation (HSCT), adrenal insufficiency treatment, gene therapy, dietary therapy, and others. In allogenic hematopoietic stem cell transplantation, affected individuals, receive hematopoietic stem cells from a healthy person, referred to as the donor. The studies showed that HSCT stops the progression of neurological disease in ALD, although it does not improve adrenal insufficiency. In gene therapy, the defective gene present in a patient is replaced with a normal gene to enable the produce of the active enzyme and prevent the development and progression of the disease.
By Distribution Channel:
On the basis of distribution channel, the Adrenoleukodystrophy Therapeutics market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment has accounted for the highest market share as the major therapeutics are prescription products. Therefore, hospital pharmacies are further anticipated also to witness growth during the forecast period.
Adrenoleukodystrophy types can be segmented into childhood cerebral ALD (CCALD), adult cerebral ALD, adrenomyeloneuropathy (AMN), and Addison’s disease. By Disease Indication, approximately two-thirds of ALD patients will present with the childhood cerebral form of the disease, which is the most severe form. Therefore, can be expected to gain higher revenue share during the forecast period.